Cargando…
Osteopontin: A Promising Therapeutic Target in Cardiac Fibrosis
Osteopontin (OPN) is recognized for its significant roles in both physiological and pathological processes. Initially, OPN was recognized as a cytokine with pro-inflammatory actions. More recently, OPN has emerged as a matricellular protein of the extracellular matrix (ECM). OPN is also known to be...
Autores principales: | Abdelaziz Mohamed, Iman, Gadeau, Alain-Pierre, Hasan, Anwarul, Abdulrahman, Nabeel, Mraiche, Fatima |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952988/ https://www.ncbi.nlm.nih.gov/pubmed/31816901 http://dx.doi.org/10.3390/cells8121558 |
Ejemplares similares
-
Na(+)/H(+) Exchanger Isoform 1-Induced Osteopontin Expression Facilitates Cardiomyocyte Hypertrophy
por: Mohamed, Iman A., et al.
Publicado: (2015) -
p90 ribosomal S6 kinase: a potential therapeutic target in lung cancer
por: Poomakkoth, Noufira, et al.
Publicado: (2016) -
Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin–angiotensin–aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study
por: Moustafa, Diala Alhaj, et al.
Publicado: (2022) -
Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression
por: Abdulrahman, Nabeel, et al.
Publicado: (2022) -
Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
por: Al-Shamasi, Al-Anood, et al.
Publicado: (2021)